BioNTech, Genentech Terminate Phase 2 Trial of mRNA Cancer Vaccine Autogene Cevumeran in Colorectal Cancer
- Autogene cevumeran is an individualized, tumor-specific neoantigen mRNA vaccine designed to trigger a T-cell response against a patient's unique tumor mutations.
- Phase 2 trial BNT122-01, run with Genentech, evaluated it as adjuvant monotherapy versus watchful waiting in ctDNA-positive patients with surgically resected Stage II (high-risk) or Stage III colorectal cancer, targeting roughly 327 enrollees with disease-free survival as the primary endpoint.
- BioNTech and Genentech terminated the trial on August 28, 2026, after an independent Data Safety Monitoring Board (DSMB) identified a numerical overall-survival imbalance disfavoring the vaccine arm and concluded continuation was unlikely to change the efficacy outcome; no new safety signals were found.
- A separate, unaffected Phase 2 trial (Imcode003) continues to evaluate autogene cevumeran combined with checkpoint inhibition and chemotherapy in adjuvant pancreatic ductal adenocarcinoma.
- BioNTech shares fell as much as 8% on the news.
An OS imbalance with no new safety signal is a different failure mode than a safety-driven halt — it indicts adjuvant monotherapy in CRC, not necessarily neoantigen mRNA vaccines as a modality. That distinction matters competitively: Moderna/Merck's V940 (INT) has paired its individualized vaccine with pembrolizumab from the outset rather than testing it solo against watchful waiting, and BioNTech's own still-running pancreatic trial (Imcode003) uses that same vaccine-plus-checkpoint-inhibitor-plus-chemo architecture. So the part of the platform that just failed is arguably its least mechanistically ambitious use case. The 8% single-day drop on one Phase 2 readout, though, is the bigger tell — it shows how much of BioNTech's valuation still rests on individualized-vaccine optionality rather than de-risked, validated pipeline.
BioNTech, Genentech terminate Phase 2 of personalized mRNA cancer vaccine ↗